AKYNZEO® is a convenient combination agent available for single administration in acute or delayed CINV*
*AKYNZEO is given with dexamethasone.
AKYNZEO is available in two formulations: Capsules and For Injection
AKYNZEO CAPSULES dosing recommendations1
|Chemotherapy Regimen||Day 1||Days 2–4|
|HEC, including cisplatin-based chemotherapy||AKYNZEO capsule||—|
|AC or other non–cisplatin-based chemotherapy||AKYNZEO capsule||—|
- One AKYNZEO capsule (300 mg netupitant/0.5 mg palonosetron) should be administered approximately 1 hour prior to the start of chemotherapy1
- Dexamethasone should be administered 30 minutes prior to chemotherapy on day 11
- AKYNZEO can be taken with or without food1
- Avoid use in patients with severe hepatic impairment, as well as severe renal impairment or end-stage renal disease1
Akynzeo For Injection Dosing Recommendations1
|Chemotherapy regimen||Day 1||Days 2–4|
|HEC, including cisplatin-based chemotherapy||AKYNZEO injection, IV over 30 min prior to therapy||--|
|Dexamethasone 12 mg||Dexamethasone 8 mg|
- AKYNZEO for injection (235 mg fosnetupitant/0.25 mg palonosetron) should be administered over 30 minutes approximately 30 minutes prior to the start of chemotherapy
- Dexamethasone (12 mg) should be administered at the time of intravenous infusion on day 1
- Efficacy of AKYNZEO for injection for the prevention of CINV has not been established in a clinical study of patients treated with AC or other moderately emetogenic chemotherapy
- Avoid use in patients with severe hepatic impairment, as well as severe renal impairment or end-stage renal disease
- Avoid use in pregnancy, limited data is available, may cause fetal harm
- =chemotherapy-induced nausea and vomiting.
- =highly emetogenic chemotherapy.